August 18, 2026
Incyte's Commitment to Responsibility
At Incyte, global responsibility is integral to how we advance innovative science and support patients. Our 2025 Global Responsibility Report highlights our commitment in action from January 1 through December 31, 2025, from advancing a differentiated pipeline to strengthening the communities where we live and work.
Patients
and Innovation
- 5+ global regulatory approvals across multiple products and advanced numerous assets from early- to late-stage development*
- 400,000+ patients treated with medicines commercialized by Incyte and ~280,000 patients assisted through U.S. patient support and copay assistance programs
- 137 ongoing clinical trials, including 21 new trials, and 15 completed trials, across 4,190 sites in 50 countries
- ~40% of revenue reinvested into R&D to advance Incyte’s growing portfolio
Community
- $1,000,000+ donated through the Incyte Charitable Giving Foundation
- ~$425,000 matched in employee giving to over 650 organizations
- 43% of our global employees used their paid volunteer day
People
- 2,800+ employees located across the U.S., Canada, Europe and Asia
- 5 workplace recognitions, including Science Magazine's Top Employers, Newsweek’s Top 100 Global Most Loved Workplaces and Best Practice Institute’s America’s Most Loved Workplaces, along with additional Newsweek recognitions for sustainability and inclusion & diversity
- 51% women employees and 43% women in leadership (director and above)
Environment
Since 2019, Incyte has demonstrated significant reductions in Scope 1 and 2 market-based greenhouse gas emission intensities:
- 51% reduction in emissions per 1,000 square feet, even as total square footage grew by 64%
- 59% decrease in emissions per employee, despite a 95% increase in employee headcount
- 67% drop in emissions per $1 million in revenue, while overall revenue grew by 138%
Learn more about our approach to research and development and our commitment to advancing innovative medicines for patients with unmet medical needs: https://incyte.com/responsibility
*Since December 31, 2025, Incyte has received one new U.S. regulatory approval.
